The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC).
Lee Steven Schwartzberg
No relevant relationships to disclose
Fernando Rivera
Research Funding - Amgen
Meinolf Karthaus
Consultant or Advisory Role - Amgen; Roche
Honoraria - Amgen; Roche
Gianpiero Fasola
Consultant or Advisory Role - Amgen
Honoraria - Merck
Jean-Luc Canon
Research Funding - Amgen
Hua Yu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Kelly S. Oliner
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
William Y. Go
Employment or Leadership Position - Amgen
Stock Ownership - Amgen